This case report highlights the use of bromocriptine in the clinical management of neuroleptic malignant syndrome induced by antipsychotic therapy.
Should not yet change NMS management; single case leaves open bromocriptine role pending controlled trials.
Neuroleptic malignant syndrome: a case treated with bromocriptine Neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome which is rarely seen during treatment with antipsychotic medications. In this paper, the treatment of NMS that developed after a dose increase in oral antipsychotic drug therapy with depot antipsychotics in a patient with schizoaffective disorder, who has used antipsychotic medications for a long time and was hospitalized many times was reported and the treatment approach and bromocriptine use in NMS was discussed.
No takes yet. Share an insight, caveat, or question.
Canbek et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: